M-A: Efficacy of amisulpride for depressive symptoms in individuals with mental disorders.

Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis – Human Psychopharmacology: Clinical & Experimental

Commentary on Twitter

MA: Amisulpride 50 mg/day was associated with a larger reduction of depressive symptoms vs. placebo (SMD= −0.70; −0.92 to −0.49; I2=0.0%), and was found to be comparable to SSRIs (SMD= −0.08; −0.23 to 0.06; I2=0.0%) in dysthymia https://t.co/schW6PbZQK pic.twitter.com/p7St9pE0Cr

— P𝘧OL (@psychopharmacol) November 7, 2021